[27N-pm] Chemical biology-5

Sun. Mar 27, 2022 1:30 PM - 2:42 PM [Room N] Conference Room 233 (Bldg. 2: 3F)

Chair: Naoya Ieda

+Add all to schedule

1:30 PM - 1:42 PM

[27N-pm01S] Malonic acid-type fullerene derivatives strongly inhibit SARS-CoV-2 main protease

○Daiki Katagishi¹, Akiko Iwasaki¹, Daisuke Yasuda², Kyoko Takahashi³, Shigeo Nakamura³, Tadahiko Mashino¹, Naoya Kumagai¹, Tomoyuki Ohe¹ (1. Faculty of Pharmacy, Keio University, 2. Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 3. Nippon Medical School)

1:42 PM - 1:54 PM

[27N-pm02S] Development of an epigenome manipulation method with synthetic catalyst systems toward a novel anti-cancer strategy

○Yuki Yamanashi¹, Kenzo Yamatsugu¹, Shigehiro Kawashima¹, Motomu Kanai¹ (1. Grad. Sch. Pharm. Sci., The Univ. of Tokyo)

1:54 PM - 2:06 PM

[27N-pm03S] Development of a selective activity-based probe for SARS-CoV-2 3CL protease

○Yuki Yamauchi¹, Narumi Yoshioka¹, Sho Konno¹, Akihiro Taguchi¹, Atsuhiko Taniguchi¹, Yoshio Hayashi¹ (1. Sch. Pharm., Tokyo Univ. of Pharm. and Life Sci.)

2:06 PM - 2:18 PM

[27N-pm04S] Reversible Lys selective worhad for development of covalent drugs

○Yuya Hirose¹, Keisuke Tokunaga¹, Yudai Tanaka¹, Naoya Shindo¹, Akio Ojida¹ (1. Grad. Sch. Pharm. Sci. Kyushu Univ.)

2:18 PM - 2:30 PM

[27N-pm05S] Development of a catalytic system for intracellular histone acylation using cell membrane permeable catalyst

○Yuto Azumaya¹, Akiko Fujimura¹, Tadashi Ishiguro¹, Hisashi Ishida², Hidetoshi Kono², Kenzo Yamatsugu¹, Shigehiro Kawashima¹, Motomu Kanai¹ (1. Grad. Sch. Pharm., The Univ. of Tokyo, 2. iQLS, QST)

2:30 PM - 2:42 PM

[27N-pm06] In vivo application of ruthenium catalyst for cancer treatment

○Kyohei Muguruma¹, Peni Ahmadi², Tsung-Che Chang², Katsunori Tanaka^1,2,3 (1. Tokyo Institute of Technology, 2. RIKEN, 3. Kazan Federal University)

Session information